Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2026 08:40 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of...
May 07, 2026 12:00 ET | Source: Edmentum

Edmentum Research Confirms Causal Impact of Virtual Tutoring on Student Achievement

Bloomington, Minn., May 07, 2026 (GLOBE NEWSWIRE) -- Edmentum, the leading provider of K-12 digital curriculum, assessments, and learning interventions, has released new efficacy research...
May 07, 2026 11:00 ET | Source: Muck Rack

Generative Pulse: Earned Media Consistently Drives AI Citations, Holding at 84%

Muck Rack’s What Is AI Reading? report analyzes how generative AI cites sources across LLMs, with insights for generative engine optimization.
May 07, 2026 09:20 ET | Source: LeonaBio, Inc.

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

LeonaBio, Inc. (NASDAQ: LONA), announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter Silverman, J.D. to its Board of Directors.
May 07, 2026 08:45 ET | Source: 24/7 Market News and NeOnc Technology

Biotech’s Next Wave May Already be in Motion

Insider conviction, late-stage clinical wins, and platform technologies are converging to reshape biotech/pharma valuations and patient outcomes.
May 07, 2026 08:23 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Final Primary Endpoint Report on Objective Response Rate data from...
May 06, 2026 18:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
May 06, 2026 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary...
May 06, 2026 13:30 ET | Source: Custom Market Insights

Global RNA Targeting Small Molecule Drug Discovery Market Size/Share Worth USD 17.6 Billion by 2035 at a 22.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)

Austin, TX, USA, May 06, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “RNA Targeting Small Molecule Drug Discovery Market Size, Trends and Insights By...
May 06, 2026 10:52 ET | Source: Redwood Logistics

Redwood Logistics® Releases AI in Logistics Report, Finding Only 13 Percent of Shippers Deploying AI Are Generating Quantifiable Results

CHICAGO, May 06, 2026 (GLOBE NEWSWIRE) -- Redwood Logistics (Redwood), one of North America’s leading modern fourth-party logistics (4PL) providers, today released its inaugural AI in Logistics...